0000000001131097

AUTHOR

Jadwiga Nessler

showing 2 related works from this author

Impact of COVID-19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV-HF-SIRIO 6 study)

2022

Abstract Aims The coronavirus disease‐2019 (COVID‐19) pandemic has changed the landscape of medical care delivery worldwide. We aimed to assess the influence of COVID‐19 pandemic on hospital admissions and in‐hospital mortality rate in patients with acute heart failure (AHF) in a retrospective, multicentre study. Methods and results From 1 January 2019 to 31 December 2020, a total of 101 433 patients were hospitalized in 24 Cardiology Departments in Poland. The number of patients admitted due to AHF decreased by 23.4% from 9853 in 2019 to 7546 in 2020 (P < 0.001). We noted a significant reduction of self‐referrals in the times of COVID‐19 pandemic accounting 27.8% (P < 0.001), with increase…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Heart failureMedical careLevodopaCOVID‐19Internal medicinePandemicmedicineHumansDiseases of the circulatory (Cardiovascular) systemIn patientPandemicsRetrospective StudiesSARS-CoV-2business.industryMortality rateCarbidopaCOVID-19Original Articlesmedicine.diseaseIn‐hospital mortalityHospitalizationDrug CombinationsIn-hospital mortalityRC666-701Heart failureConcomitantAcute DiseaseOriginal ArticleCardiology and Cardiovascular MedicinebusinessHospital stayESC heart failure
researchProduct

Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design

2022

Abstract Purpose Clinical practice forces the necessity to conduct a clinical trial concerning the group of outpatients with chronically advanced heart failure in III or IV NYHA functional class, frequently requiring hospitalizations due to HF exacerbation, and often left without any additional therapeutic option. The current trial aims to determine the efficacy and safety of repeated levosimendan infusions in the group of severe outpatients with reduced ejection fraction (HFrEF). Material and methods LEIA-HF (LEvosimendan In Ambulatory Heart Failure Patients) is a multicentre, randomized, double-blind, placebo-controlled, phase 4 clinical trial to determine whether the repetitive use of le…

Heart Failuremedicine.medical_specialtyCardiotonic AgentsEjection fractionExacerbationbusiness.industryStroke VolumeGeneral MedicineLevosimendanPlacebomedicine.diseaseClinical trialTreatment OutcomeDouble-Blind MethodHeart failureEmergency medicineAmbulatoryClinical endpointmedicineHumansbusinessSimendanmedicine.drugAdvances in Medical Sciences
researchProduct